<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261053</url>
  </required_header>
  <id_info>
    <org_study_id>C1 1202-01</org_study_id>
    <nct_id>NCT00261053</nct_id>
  </id_info>
  <brief_title>Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema</brief_title>
  <official_title>A Phase II Exploratory, Open-label Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this single-center study is to explore the efficacy, safety, tolerability and
      pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute
      attacks in patients with hereditary angioedema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcomes: Relief of angioedema symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes: Safety and tolerability; pharmacokinetics/pharmacodynamics</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Genetic Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label i.v. administration of 100 U/kg rhC1INH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>i.v. recombinant human C1 inhibitor</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  Clinical and laboratory diagnosis of HAE

          -  Plasma level of functional C1INH of less than 50% of normal

          -  Severe attack of abdominal, facial-oro-pharyngeal, genito-urinary and/or peripheral
             HAE.

        Main exclusion Criteria:

          -  Acquired angioedema

          -  Pregnancy or breastfeeding

          -  Participation in another clinical study within prior 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Nuijens, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharming Technologies B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For information contact Sonja Visscher</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2005</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

